M. James Lenhard, Jr., M.D.

Our Experts

Back to all Experts
James Lenhard, Jr., M.D., FACE, FACEP

James Lenhard, Jr., M.D., FACE, FACEP

Medical Director

Expertise & Research Interests

  • Diabetes & Stabilizing Blood Sugar
  • Internal Medicine
  • Thyroid Conditions
  • Endocrinology
  • Diabetes Care
  • Diabates Prevention
  • Diabetes & Frailty in Older Adults
  • Autonomic Dysfunction


  • MD, Albany Medical College
  • BS, Biochemistry, Cornell University

James Lenhard, Jr., M.D., FACE, FACEP

Medical Director

Dr. James Lenhard is an international expert on diabetes care and research and has been recognized through the Diabetes Physician Recognition Program for providing high-quality care to diabetes patients.

He oversees ChristianaCare's Metabolic Health Services, the Diabetes & Metabolic Research Center and ChristianaCare's Weight Management Center. He is frequently interviewed by national news media on diabetes topics.


of 09


Downloadable Images and Links
Media Appearances

8 Easy, Meaningful New Year’s Resolutions for Better Health

2018-01-02 , New York Times
Dr. M. James Lenhard, medical director of Christiana Care Health System’s Diabetes & Metabolic Diseases Center in Wilmington, Del., agreed that making it fun is paramount.

Beating diabetes: Meld medicine with lifestyle changes

2016-04-24 , The News Journal
Christiana Care Health System started its bariatric surgery program in 2001, four years after launching its weight management program. Roughly 25 to 30 percent of enrollees in both programs have diabetes, according to James Lenhard, medical director of Christiana’s Diabetes and Metabolic Diseases Center and Weight Management Center.

Diabetes: Delaware's billion-dollar crisis

2016-04-23 , The News Journal
The average person is diagnosed with Type 2 five to seven years after living with prediabetes, according to Christiana endocrinologist James Lenhard. Some patients experience no symptoms warning them of trouble ahead.

Attacking type 2 diabetes with meds

2016-03-24 , The News Journal
"All the diabetes medications are approved for one thing only and that's lowering blood sugar," said Dr. James Lenhard, medical director of Christiana Care Health System’s Diabetes and Metabolic Diseases Center and Christiana Care’s Weight Management Center.

Weight loss meds: friend or foe?

2016-03-23 , The News Journal
"Insurance almost never covers the costs," said Dr. James Lenhard, medical director of Christiana Care Health System’s Diabetes and Metabolic Diseases Center and Christiana Care’s Weight Management Center.
Selected Papers and Publications

Insulin therapy for the treatment of type 1 diabetes during pregnancy

2013-11-07 , The Journal of Maternal-Fetal & Neonatal Medicine
Pregnancies affected by type 1 diabetes (T1D) carry a major risk for poor fetal, neonatal and maternal outcomes. Achieving normoglycemia while minimizing the risk of hypoglycemia is a major goal in the management of T1D as this can greatly reduce the risk of complications. However, maintaining optimal glucose levels is challenging because insulin requirements are not uniform throughout the course of the pregnancy.

Effects of surgically induced weight loss by Roux-en-Y gastric bypass on cardiovascular autonomic nerve function

2013-04-01 , Surgery for Obesity and Related Diseases
Obesity is associated with autonomic imbalance. With respect to cardiovascular autonomic dysfunction, this is characterized by reduced heart rate variability (HRV). Our objective was to determine the effect of surgically induced weight loss on cardiovascular autonomic nerve fiber function in subjects with severe obesity and examine whether an association with reduced insulin resistance exists. The setting was a hospital and private practice in the United States.

Hip Strength in Adults With Type 1 Diabetes is Associated With Age at Onset of Diabetes

2012-03-01 , Journal of Clinical Densitometry
We investigated the association of age at onset of type 1 diabetes with areal bone mineral density (aBMD), estimates of bone strength, and outer diameter. Using dual-energy X-ray absorptiometry (DXA), aBMD, axial strength (cross-sectional area [CSA]), bending strength (section modulus [SM]), and outer diameter at the narrow neck, intertrochanter, and shaft of the proximal femur were determined for 60 adults.

Autonomic nerve fiber function and bone mineral density in individuals with type 1 diabetes: A cross-sectional study

2009-06-01 , Diabetes Research and Clinical Practice
Experimental models support a role for the sympathetic nervous system in bone metabolism. Beta-adrenoreceptors have been demonstrated on osteoblast-like cells. Beta-blocker use is associated with higher bone mineral density (BMD) in some epidemiologic studies. The aim of this study was to determine if measures of the autonomic nervous system (ANS) were associated with reduced BMD in type 1 diabetes.